The study will enroll patients from over 10 government and private hospitals and is expected to be completed by July or August, Glenmark said. Per the clinical protocol, 150 subjects will be enrolled in a randomized study in a 1-1 ratio to favipiravir with standard supportive care or standalone standard supportive care. Treatment will be given for a maximum of 14 days.

Glenmark developed the active pharmaceutical ingredient (API) and formulations for the product in-house. If commercialized, the molecule will be marketed in India under the brand name FabiFlu. Favipiravir has already been approved for use in Japan.

Pangolin genome offers insight into SARS-CoV-2's jump to humans
Research into the source of SARS-CoV-2 in China has focused on pangolins, anteater-like mammals that may have harbored the virus before it jumped to humans....

Sorrento, Mount Sinai to develop targeted SARS-CoV-2 antibody treatment
Sorrento Therapeutics and Mount Sinai Health System have joined forces to develop an antibody therapy called COVI-Shield to treat COVID-19.

Scientists explore varying immune responses in COVID-19 patients
A new study aims to further classify the immune response of COVID-19 patients with the goal of understanding the pathogenesis of the disease and accelerating...

Researchers investigate how a potent mAb blocks SARS-CoV-2
Based on previous research that explored therapies against SARS-CoV, a new report has identified a fully human monoclonal antibody (mAb) that prevents...

Cytokine storm may cause T-cell exhaustion in COVID-19 cases
Cytokine storms may impact the severity of COVID-19 cases by lowering T-cell populations, according to a study published in Frontiers in Immunology...